EP2152754B8 - Monoclonal antibodies against claudin-18 for treatment of cancer - Google Patents

Monoclonal antibodies against claudin-18 for treatment of cancer Download PDF

Info

Publication number
EP2152754B8
EP2152754B8 EP08758782.0A EP08758782A EP2152754B8 EP 2152754 B8 EP2152754 B8 EP 2152754B8 EP 08758782 A EP08758782 A EP 08758782A EP 2152754 B8 EP2152754 B8 EP 2152754B8
Authority
EP
European Patent Office
Prior art keywords
cancer
treatment
monoclonal antibodies
antibodies against
against claudin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP08758782.0A
Other languages
German (de)
French (fr)
Other versions
EP2152754A2 (en
EP2152754B1 (en
Inventor
Ugur Sahin
Özlem TÜRECI
Gunda Brandenburg
Dirk Usener
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TRON Translationale Onkologie an der Universitaetsmedizin der Johannes Gutenberg Universitaet Mainz gGmbH
Astellas Pharma Inc
Original Assignee
Ganymed Pharmaceuticals GmbH
TRON Translationale Onkologie an der Universitaetsmedizin der Johannes Gutenberg Universitaet Mainz gGmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ganymed Pharmaceuticals GmbH, TRON Translationale Onkologie an der Universitaetsmedizin der Johannes Gutenberg Universitaet Mainz gGmbH filed Critical Ganymed Pharmaceuticals GmbH
Priority to DK18168460.6T priority Critical patent/DK3401334T3/en
Priority to EP23155995.6A priority patent/EP4242236A3/en
Priority to EP18168460.6A priority patent/EP3401334B1/en
Priority to EP08758782.0A priority patent/EP2152754B8/en
Publication of EP2152754A2 publication Critical patent/EP2152754A2/en
Application granted granted Critical
Publication of EP2152754B1 publication Critical patent/EP2152754B1/en
Publication of EP2152754B8 publication Critical patent/EP2152754B8/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
EP08758782.0A 2007-05-29 2008-05-27 Monoclonal antibodies against claudin-18 for treatment of cancer Active EP2152754B8 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
DK18168460.6T DK3401334T3 (en) 2007-05-29 2008-05-27 MONOCLONAL ANTIBODIES AGAINST CLAUDIN-18 FOR CANCER TREATMENT
EP23155995.6A EP4242236A3 (en) 2007-05-29 2008-05-27 Monoclonal antibodies against claudin-18 for treatment of cancer
EP18168460.6A EP3401334B1 (en) 2007-05-29 2008-05-27 Monoclonal antibodies against claudin-18 for treatment of cancer
EP08758782.0A EP2152754B8 (en) 2007-05-29 2008-05-27 Monoclonal antibodies against claudin-18 for treatment of cancer

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US93209907P 2007-05-29 2007-05-29
EP07010622A EP1997832A1 (en) 2007-05-29 2007-05-29 Monoclonal antibodies against Claudin-18 for treatment of cancer
PCT/EP2008/004197 WO2008145338A2 (en) 2007-05-29 2008-05-27 Monoclonal antibodies against claudin-18 for treatment of cancer
EP08758782.0A EP2152754B8 (en) 2007-05-29 2008-05-27 Monoclonal antibodies against claudin-18 for treatment of cancer

Related Child Applications (3)

Application Number Title Priority Date Filing Date
EP18168460.6A Division EP3401334B1 (en) 2007-05-29 2008-05-27 Monoclonal antibodies against claudin-18 for treatment of cancer
EP18168460.6A Division-Into EP3401334B1 (en) 2007-05-29 2008-05-27 Monoclonal antibodies against claudin-18 for treatment of cancer
EP23155995.6A Division EP4242236A3 (en) 2007-05-29 2008-05-27 Monoclonal antibodies against claudin-18 for treatment of cancer

Publications (3)

Publication Number Publication Date
EP2152754A2 EP2152754A2 (en) 2010-02-17
EP2152754B1 EP2152754B1 (en) 2018-04-25
EP2152754B8 true EP2152754B8 (en) 2018-07-04

Family

ID=38650052

Family Applications (4)

Application Number Title Priority Date Filing Date
EP07010622A Withdrawn EP1997832A1 (en) 2007-05-29 2007-05-29 Monoclonal antibodies against Claudin-18 for treatment of cancer
EP18168460.6A Active EP3401334B1 (en) 2007-05-29 2008-05-27 Monoclonal antibodies against claudin-18 for treatment of cancer
EP08758782.0A Active EP2152754B8 (en) 2007-05-29 2008-05-27 Monoclonal antibodies against claudin-18 for treatment of cancer
EP23155995.6A Pending EP4242236A3 (en) 2007-05-29 2008-05-27 Monoclonal antibodies against claudin-18 for treatment of cancer

Family Applications Before (2)

Application Number Title Priority Date Filing Date
EP07010622A Withdrawn EP1997832A1 (en) 2007-05-29 2007-05-29 Monoclonal antibodies against Claudin-18 for treatment of cancer
EP18168460.6A Active EP3401334B1 (en) 2007-05-29 2008-05-27 Monoclonal antibodies against claudin-18 for treatment of cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP23155995.6A Pending EP4242236A3 (en) 2007-05-29 2008-05-27 Monoclonal antibodies against claudin-18 for treatment of cancer

Country Status (24)

Country Link
US (1) US8425902B2 (en)
EP (4) EP1997832A1 (en)
JP (3) JP5816431B2 (en)
KR (3) KR101585990B1 (en)
CN (2) CN103694353B (en)
BR (1) BRPI0811907A2 (en)
CA (1) CA2687206C (en)
DK (1) DK3401334T3 (en)
ES (2) ES2675375T3 (en)
FI (1) FI3401334T3 (en)
HR (1) HRP20230282T3 (en)
HU (1) HUE061795T2 (en)
IL (3) IL201666A (en)
LT (1) LT3401334T (en)
MX (1) MX2009012906A (en)
NZ (1) NZ581365A (en)
PL (1) PL3401334T3 (en)
PT (1) PT3401334T (en)
RS (1) RS64065B1 (en)
RU (2) RU2571923C2 (en)
SG (1) SG183773A1 (en)
SI (1) SI3401334T1 (en)
WO (1) WO2008145338A2 (en)
ZA (1) ZA200907675B (en)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6358588A (en) * 1986-08-29 1988-03-14 Toshiba Corp Bar code reader
DE10254601A1 (en) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Gene products differentially expressed in tumors and their use
DE102004024617A1 (en) * 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentially expressed in tumors gene products and their use
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
WO2009086197A1 (en) 2007-12-20 2009-07-09 Monogram Biosciences, Inc. Her-2 diagnostic methods
EP2282769A4 (en) 2008-04-29 2012-04-25 Abbott Lab Dual variable domain immunoglobulins and uses thereof
JP2011523853A (en) 2008-06-03 2011-08-25 アボット・ラボラトリーズ Dual variable domain immunoglobulins and uses thereof
KR20110016959A (en) 2008-06-03 2011-02-18 아보트 러보러터리즈 Dual variable domain immunoglobulins and uses thereof
SG192489A1 (en) 2008-07-08 2013-08-30 Abbott Lab Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
US8349574B2 (en) 2009-01-15 2013-01-08 Laboratory Corporation Of America Holdings Methods of determining patient response by measurement of Her-3
US8470542B2 (en) 2008-12-01 2013-06-25 Laboratory Corporation Of America Holdings Methods and assays for measuring p95 and/or p95 complexes in a sample and antibodies specific for p95
CN107028969A (en) 2009-02-20 2017-08-11 加尼梅德药物公司 For cancer diagnosis and the method and composition for the treatment of
MX2011011670A (en) * 2009-05-01 2011-11-18 Abbott Lab Dual variable domain immunoglobulins and uses thereof.
SG178602A1 (en) 2009-09-01 2012-04-27 Abbott Lab Dual variable domain immunoglobulins and uses thereof
BR112012008833A2 (en) 2009-10-15 2015-09-08 Abbott Lab double variable domain immunoglobulins and uses thereof
UY32979A (en) 2009-10-28 2011-02-28 Abbott Lab IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
LT2499161T (en) 2009-11-11 2017-11-27 Ganymed Pharmaceuticals Gmbh Antibodies specific for claudin 6 (cldn6)
TR201809413T4 (en) * 2010-03-16 2018-07-23 Biontech Protein Therapeutics Gmbh Tumor inoculation containing a humoral immune response to self-protein cldn18.2.
EP2366709A1 (en) * 2010-03-16 2011-09-21 BioNTech AG Tumor vaccination involving a humoral immune response against self-proteins
EP2404936A1 (en) * 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
MX341579B (en) 2010-08-03 2016-08-25 Abbvie Inc * Dual variable domain immunoglobulins and uses thereof.
AU2011293253B2 (en) 2010-08-26 2014-12-11 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
ES2683953T3 (en) * 2011-02-07 2018-09-28 Aggamin Llc Procedures and systems to treat or prevent gestational hypertensive disorders
WO2012149356A2 (en) * 2011-04-29 2012-11-01 Apexigen, Inc. Anti-cd40 antibodies and methods of use
NZ724296A (en) 2011-05-13 2020-05-29 Ganymed Pharmaceuticals Ag Antibodies for treatment of cancer expressing claudin 6
CA2861610A1 (en) 2011-12-30 2013-07-04 Abbvie Inc. Dual specific binding proteins directed against il-13 and/or il-17
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
DK3254695T3 (en) * 2012-05-23 2020-11-30 Astellas Pharma Inc COMBINATION THERAPY INVOLVING CLAUDIN 18.2 ANTIBODIES FOR CANCER TREATMENT
WO2013174404A1 (en) * 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2013174403A1 (en) * 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
EP3725810B1 (en) 2012-05-23 2022-07-06 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
TW202210507A (en) 2012-11-01 2022-03-16 美商艾伯維有限公司 Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
KR102381936B1 (en) * 2012-11-13 2022-04-01 비온테크 에스이 Agents for treatment of claudin expressing cancer diseases
EP4177273A1 (en) * 2013-02-20 2023-05-10 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014127785A1 (en) * 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
US9062108B2 (en) 2013-03-15 2015-06-23 Abbvie Inc. Dual specific binding proteins directed against IL-1 and/or IL-17
WO2014146672A1 (en) 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2015014376A1 (en) 2013-07-31 2015-02-05 Biontech Ag Diagnosis and therapy of cancer involving cancer stem cells
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
WO2016165762A1 (en) * 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Drug conjugates comprising antibodies against claudin 18.2
WO2016180468A1 (en) * 2015-05-11 2016-11-17 Biontech Cell & Gene Therapies Gmbh Claudin-18.2-specific immunoreceptors and t cell epitopes
TW201710286A (en) 2015-06-15 2017-03-16 艾伯維有限公司 Binding proteins against VEGF, PDGF, and/or their receptors
WO2018089300A1 (en) * 2016-11-10 2018-05-17 Merck Sharp & Dohme Corp. Ilt3 ligand
WO2018148595A1 (en) * 2017-02-10 2018-08-16 Washington University Antibodies to tip1 and methods of use thereof
US20180298094A1 (en) * 2017-04-17 2018-10-18 Ksl Biomedical Llc Monoclonal antibodies targeted to human taxilin alpha and methods for use of same
EP3613772A4 (en) * 2017-04-18 2020-12-30 Good T Cells, Inc. Binding molecule specific for lrig-1 protein and use thereof
CN107779500A (en) * 2017-10-25 2018-03-09 上海药明生物技术有限公司 A kind of sequence measurement and primer sequence of quick obtaining Rat hybridoma cell monoclonal antibodies sequence
EP3762031A4 (en) * 2018-03-08 2021-12-22 Phanes Therapeutics, Inc. Anti-claudin 18.2 antibodies and uses thereof
WO2019175223A1 (en) * 2018-03-13 2019-09-19 Tusk Therapeutics Ltd Anti-cd25 for tumour specific cell depletion
CN112166123B (en) * 2018-03-14 2022-09-30 北京轩义医药科技有限公司 Anti-claudin 18.2 antibodies
CN110862454B (en) * 2018-08-27 2022-12-30 南京圣和药业股份有限公司 anti-Claudin 18_2 antibody and application thereof
SG11202105885WA (en) * 2018-12-07 2021-07-29 Zlip Holding Ltd Anti-claudin antibodies and uses thereof
SG11202106534RA (en) * 2018-12-28 2021-07-29 Nanjing Genscript Biotech Co Ltd Claudin18.2 binding moieties and uses thereof
CN113166246A (en) * 2018-12-28 2021-07-23 四川科伦博泰生物医药股份有限公司 Antibody and application thereof
CN113817061B (en) * 2019-01-15 2022-11-04 浙江道尔生物科技有限公司 anti-CLD18A2 single domain antibody and anti-tumor application thereof
CN109762067B (en) * 2019-01-17 2020-02-28 北京天广实生物技术股份有限公司 Antibodies that bind human Claudin18.2 and uses thereof
EP3917564A4 (en) * 2019-02-01 2022-12-21 NovaRock Biotherapeutics, Ltd. Anti-claudin 18 antibodies and methods of use thereof
US20220185881A1 (en) * 2019-04-01 2022-06-16 Jiangsu Hengrui Medicine Co., Ltd. Anti-claudin 18.2 antibody and application thereof
CN111978402B (en) * 2019-05-24 2022-06-28 三优生物医药(上海)有限公司 Novel CLDN18.2 binding molecules
CN114206935B (en) * 2019-05-24 2024-01-12 三优生物医药(上海)有限公司 Novel CLDN18.2 binding molecules
CA3146665A1 (en) * 2019-07-17 2021-01-21 The Regents Of The University Of California Claudin18 antibodies and methods of treating cancer
TW202120558A (en) * 2019-08-20 2021-06-01 中國大陸商邁博斯生物醫藥(蘇州)有限公司 Novel anti- cldn18.2 antibodies
CN112574307B (en) * 2019-09-29 2023-11-28 迈威(上海)生物科技股份有限公司 Anti-human Claudin18.2 antibody and application thereof
AU2020398045A1 (en) 2019-12-06 2022-06-09 Sotio Biotech A.S. Humanized CLDN18.2 antibodies
PE20221830A1 (en) 2019-12-23 2022-11-29 Sotio Biotech A S SPECIFIC ANTIBODIES AGAINST CLAUDIN 18.2 TUMOR
AU2021204861A1 (en) * 2020-01-03 2022-07-28 Crage Medical Co., Limited Anti-claudin 18.2 antibody and use thereof
CN115397856A (en) 2020-03-30 2022-11-25 生物技术公司 RNA compositions targeting claudin-18.2
CN113493515B (en) * 2020-04-02 2023-03-28 广东菲鹏制药股份有限公司 anti-CLDN 18A2 antibody and drug for treating tumor
IL298184A (en) * 2020-05-15 2023-01-01 Sichuan Kelun Biotech Biopharmaceutical Co Ltd Antibody drug conjugate, preparation method therefor and use thereof
CN113929780A (en) * 2020-07-13 2022-01-14 北京凯因科技股份有限公司 Humanized antibody for treating cancer by combining claudin
WO2022011531A1 (en) * 2020-07-14 2022-01-20 浙江道尔生物科技有限公司 Anti-cld18a2 single-domain antibody
WO2022122709A1 (en) 2020-12-07 2022-06-16 Sotio Biotech A.S. Antibody-drug conjugates based on humanized cldn18.2 antibodies
WO2022140556A1 (en) * 2020-12-22 2022-06-30 Eutropics Pharmaceuticals, Inc. Methods and compositions related to bcl2 and bim heterodimer antibodies
IL302894A (en) 2020-12-23 2023-07-01 Sotio Biotech A S Tumor-specific claudin 18.2 antibody-drug conjugates
WO2023161457A1 (en) 2022-02-27 2023-08-31 Evobright Gmbh Bispecific antibodies against cd277 and a tumor-antigen
CN114836388A (en) * 2022-06-07 2022-08-02 江苏亲科生物研究中心有限公司 Claudin18.2 monoclonal antibody, preparation method and application thereof
WO2024074634A1 (en) 2022-10-06 2024-04-11 BioNTech SE Rna compositions targeting claudin-18.2
WO2024074211A1 (en) 2022-10-06 2024-04-11 BioNTech SE Rna compositions targeting claudin-18.2

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4954617A (en) 1986-07-07 1990-09-04 Trustees Of Dartmouth College Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
EP0623679B1 (en) 1987-05-21 2003-06-25 Micromet AG Targeted multifunctional proteins
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
CA2070995A1 (en) 1989-12-27 1991-06-28 Thomas E. Kmiecik Diagnostic probe for detecting human stomach cancer
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
GB9223377D0 (en) 1992-11-04 1992-12-23 Medarex Inc Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
EP2044839A3 (en) 2000-08-03 2009-07-01 Therapeutic Human Polyclonals, Inc. Production of humanized antibodies in transgenic animals
GB0020685D0 (en) * 2000-08-22 2000-10-11 Novartis Ag Organic compounds
ES2295228T3 (en) 2000-11-30 2008-04-16 Medarex, Inc. TRANSGROMIC TRANSCROMOSOMIC ROLLERS FOR THE PREPARATION OF HUMAN ANTIBODIES.
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
RU2005100777A (en) * 2002-06-14 2005-08-27 Иммуномедикс, Инк. (Us) MONOCLONAL ANTIBODY RAM4 AND ITS APPLICATION FOR DIAGNOSIS AND TREATMENT OF Pancreatic Cancer
ES2562177T3 (en) * 2002-09-27 2016-03-02 Xencor Inc. Optimized Fc variants and methods for their generation
KR100944575B1 (en) 2002-10-17 2010-02-25 젠맵 에이/에스 Human monoclonal antibodies against cd20
DE10254601A1 (en) * 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Gene products differentially expressed in tumors and their use
US20050255041A1 (en) 2004-05-13 2005-11-17 Arius Research, Inc. Cancerous disease modifying antibodies
CA2627873A1 (en) * 2005-10-31 2007-05-10 Scott Wilhelm Treatment of cancer with sorafenib
EP1790664A1 (en) * 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer

Also Published As

Publication number Publication date
CN101687929B (en) 2013-11-13
CN101687929A (en) 2010-03-31
ZA200907675B (en) 2011-04-28
RU2682285C2 (en) 2019-03-18
US20100166779A1 (en) 2010-07-01
RU2015149617A3 (en) 2019-02-04
CA2687206C (en) 2019-07-16
EP4242236A2 (en) 2023-09-13
CN103694353A (en) 2014-04-02
KR20150023951A (en) 2015-03-05
MX2009012906A (en) 2010-01-25
DK3401334T3 (en) 2023-03-27
PT3401334T (en) 2023-03-27
AU2008256489A1 (en) 2008-12-04
HRP20230282T3 (en) 2023-05-12
JP2010528075A (en) 2010-08-19
ES2675375T3 (en) 2018-07-10
RU2009149205A (en) 2011-07-10
EP2152754A2 (en) 2010-02-17
EP4242236A3 (en) 2023-11-22
RU2015149617A (en) 2019-01-14
KR101751965B1 (en) 2017-07-11
EP1997832A1 (en) 2008-12-03
JP6337053B2 (en) 2018-06-06
JP2017048170A (en) 2017-03-09
EP3401334A1 (en) 2018-11-14
WO2008145338A3 (en) 2009-02-12
NZ581365A (en) 2012-02-24
IL238667A0 (en) 2015-06-30
JP2015007053A (en) 2015-01-15
IL238668A0 (en) 2015-06-30
PL3401334T3 (en) 2023-05-15
WO2008145338A2 (en) 2008-12-04
JP5995919B2 (en) 2016-09-21
EP3401334B1 (en) 2023-02-15
KR20170005160A (en) 2017-01-11
RU2571923C2 (en) 2015-12-27
SI3401334T1 (en) 2023-05-31
RS64065B1 (en) 2023-04-28
BRPI0811907A2 (en) 2014-11-18
LT3401334T (en) 2023-03-27
CA2687206A1 (en) 2008-12-04
HUE061795T2 (en) 2023-08-28
KR101693365B1 (en) 2017-01-06
KR101585990B1 (en) 2016-01-19
SG183773A1 (en) 2012-09-27
ES2940775T3 (en) 2023-05-11
US8425902B2 (en) 2013-04-23
IL201666A0 (en) 2010-05-31
JP5816431B2 (en) 2015-11-18
EP2152754B1 (en) 2018-04-25
KR20100021573A (en) 2010-02-25
FI3401334T3 (en) 2023-03-17
IL201666A (en) 2016-03-31
CN103694353B (en) 2017-12-12

Similar Documents

Publication Publication Date Title
EP2152754B8 (en) Monoclonal antibodies against claudin-18 for treatment of cancer
HRP20181565T1 (en) Monoclonal antibodies against claudin-18 for treatment of cancer
HK1253579A1 (en) Monoclonal anti-gt468 antibodies for treatment of cancer
HRP20180485T1 (en) Monoclonal antibodies for treatment of cancer

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20091015

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1140783

Country of ref document: HK

RIN1 Information on inventor provided before grant (corrected)

Inventor name: TUERECI, OEZLEM

Inventor name: BRANDENBURG, GUNDA

Inventor name: SAHIN, UGUR

Inventor name: USENER, DIRK

17Q First examination report despatched

Effective date: 20120709

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: GANYMED PHARMACEUTICALS AG

Owner name: JOHANNES-GUTENBERG-UNIVERSITAET MAINZ

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20160808

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTC Intention to grant announced (deleted)
INTG Intention to grant announced

Effective date: 20170407

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/30 20060101AFI20170329BHEP

Ipc: A61K 39/395 20060101ALI20170329BHEP

Ipc: A61P 35/00 20060101ALI20170329BHEP

Ipc: C12N 5/12 20060101ALI20170329BHEP

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTC Intention to grant announced (deleted)
INTG Intention to grant announced

Effective date: 20170803

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 992795

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180515

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

RAP2 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: JOHANNES-GUTENBERG-UNIVERSITAET MAINZ

Owner name: GANYMED PHARMACEUTICALS GMBH

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602008054999

Country of ref document: DE

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 11

RAP2 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: GANYMED PHARMACEUTICALS GMBH

Owner name: TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITAE

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2675375

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20180710

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: MICHELI AND CIE SA, CH

Ref country code: CH

Ref legal event code: PUE

Owner name: ASTELLAS PHARMA INC., DE

Free format text: FORMER OWNER: JOHANNES-GUTENBERG-UNIVERSITAET MAINZ, DE

RAP2 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITAE

Owner name: ASTELLAS PHARMA INC.

REG Reference to a national code

Ref country code: DE

Ref legal event code: R081

Ref document number: 602008054999

Country of ref document: DE

Owner name: TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERS, DE

Free format text: FORMER OWNERS: GANYMED PHARMACEUTICALS AG, 55131 MAINZ, DE; JOHANNES-GUTENBERG-UNIVERSITAET MAINZ, 55122 MAINZ, DE

Ref country code: DE

Ref legal event code: R081

Ref document number: 602008054999

Country of ref document: DE

Owner name: ASTELLAS PHARMA INC., JP

Free format text: FORMER OWNERS: GANYMED PHARMACEUTICALS AG, 55131 MAINZ, DE; JOHANNES-GUTENBERG-UNIVERSITAET MAINZ, 55122 MAINZ, DE

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 602008054999

Country of ref document: DE

Representative=s name: ZWICKER SCHNAPPAUF & PARTNER PATENTANWAELTE PA, DE

Ref country code: DE

Ref legal event code: R082

Ref document number: 602008054999

Country of ref document: DE

Representative=s name: ZSP PATENTANWAELTE PARTG MBB, DE

Ref country code: DE

Ref legal event code: R081

Ref document number: 602008054999

Country of ref document: DE

Owner name: TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERS, DE

Free format text: FORMER OWNERS: GANYMED PHARMACEUTICALS GMBH, 55131 MAINZ, DE; JOHANNES-GUTENBERG-UNIVERSITAET MAINZ, 55122 MAINZ, DE

Ref country code: DE

Ref legal event code: R081

Ref document number: 602008054999

Country of ref document: DE

Owner name: ASTELLAS PHARMA INC., JP

Free format text: FORMER OWNERS: GANYMED PHARMACEUTICALS GMBH, 55131 MAINZ, DE; JOHANNES-GUTENBERG-UNIVERSITAET MAINZ, 55122 MAINZ, DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20180719 AND 20180725

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: NL

Ref legal event code: PD

Owner name: TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITAE

Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), ASSIGNMENT; FORMER OWNER NAME: JOHANNES-GUTENBERG-UNIVERSITAET MAINZ

Effective date: 20180704

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180425

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180425

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180725

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180725

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180425

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180425

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180425

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180425

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180726

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 992795

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180425

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180827

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602008054999

Country of ref document: DE

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20180531

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180425

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180425

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180425

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180425

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180425

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180425

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180425

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180527

26N No opposition filed

Effective date: 20190128

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180527

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180531

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180425

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 602008054999

Country of ref document: DE

Representative=s name: ZWICKER SCHNAPPAUF & PARTNER PATENTANWAELTE PA, DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180527

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180425

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20080527

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180425

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180825

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20230526

Year of fee payment: 16

Ref country code: IT

Payment date: 20230519

Year of fee payment: 16

Ref country code: FR

Payment date: 20230525

Year of fee payment: 16

Ref country code: ES

Payment date: 20230601

Year of fee payment: 16

Ref country code: DE

Payment date: 20230530

Year of fee payment: 16

Ref country code: CH

Payment date: 20230610

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20230529

Year of fee payment: 16